Search
Suvorexant
go.drugbank.com/drugs/DB09034ApprovedInvestigationalSuvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: BELSOMRA® 20 MG, BELSOMRA® 15 MGBosutinib
go.drugbank.com/drugs/DB06616ApprovedInvestigationalBosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive … Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.
Categories: Heterocyclic Compounds, 2-Ring, P-glycoprotein substrates with a Narrow Therapeutic IndexSynonyms: 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrileSulthiame
go.drugbank.com/drugs/DB08329ApprovedCategories: Heterocyclic Compounds, 1-RingProducts: Ospolot 200 mg Filmtabletten, Ospolot 50 mg FilmtablettenBromazepam
go.drugbank.com/drugs/DB01558ApprovedIllicitIt is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances. It is a intermediate-acting benzodiazepine.
Categories: Heterocyclic Compounds, 2-Ring, Cytochrome P-450 SubstratesProducts: LEXOTAN® TABLETAS 6 MG., LEXOTAN TABLET 3 mgLorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalLorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018 … approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a
Categories: MATE 1 Inhibitors, P-glycoprotein inducersProducts: LORBRENA® 25 MG, LORVIQUA (TABLETS 25 MG)Alitretinoin
go.drugbank.com/drugs/DB00523ApprovedTretinoin, also known as retinoic acid and derived from maternal vitamin A, is essential for normal growth; and embryonic development. An excess of tretinoin can be teratogenic.
Mixtures: Clindamycin 1% / Niacinamide 4% / Tretinoin 0.05%Categories: Vitamin A, P-glycoprotein substratesEplerenone
go.drugbank.com/drugs/DB00700ApprovedInvestigationalEplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: ACENOL® 25 MG, INSPRA 25 MGOctinoxate
go.drugbank.com/drugs/DB09496ApprovedInvestigationalIt was originally developed in 1950's as an organic UV-B filter that absorbs UV-B rays from sun. … Octinoxate is a cinnamate ester and common ingredient in sunscreen and other skin care products to minimize DNA photodamage.
Mixtures: Gongjinhyang Mi Luxury Foundation 2, Whoo Gongjinhyang Mi Make Up Pact 2Categories: Compounds used in a research, industrial, or household settingVericiguat
go.drugbank.com/drugs/DB15456ApprovedInvestigational[A227458,A227488] Cyclic GMP acts as a second messenger, activating a number of downstream signaling cascades that elicit a broad variety of effects, and these diverse cellular effects have implicated … [A227458] As a direct stimulator of sGC, vericiguat mitigates the need for a functional NO-sGC-cGMP axis and thereby helps to prevent the myocardial and vascular dysfunction associated with decreased sGC
Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-RingProducts: VERQUVO 5 MG FİLM KAPLI TABLET , 28 ADET, VERQUVO 2,5 MG FİLM KAPLI TABLET , 28 ADETMaraviroc
go.drugbank.com/drugs/DB04835ApprovedInvestigationalMaraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingProducts: CELSENTRI® 150 MG, CELSENTRI® 300 MG